Promising treatment for women with breast cancer

Presented this Sunday at the Cancer Congress in Chicago (United States), a new anti-HER2 targeted therapy could in the future make it possible to treat half of women with breast cancer, ie 30,000 people each year in France.

According to

, an international study published the same day in the

recalled that this treatment, which has existed for a year, works in patients whose tumor has the HER2 protein.

Previously, this protein had to be present in large quantities for the treatment to be effective, which only concerned 2,000 to 3,000 women in France.

However, according to scientific research, cases with this protein in smaller quantities can also be treated by means of this therapy, which raises to 5,000 the number of women concerned in our country.

And maybe much more.

Towards a more personalized medicine

Indeed, the next step will consist for researchers in trying to adapt the treatment called Trastuzumab Deruxtecan to the increasingly early stages of cancer, in order to no longer increase the amount of remaining life of those affected but rather the rates of healing.

This could concern half of the 60,000 cases of breast cancer diagnosed each year in France.

France Info

also indicates that this targeted therapy could lead to a reduction in the use of chemotherapy, which is sometimes poorly tolerated by patients.

Finally, this therapy opens the way to more personalized medicine with the possible development of other proteins, which would allow caregivers to focus no longer on the organ affected by the cancer but on the type of tumor that is appropriate. to fight.

​

website

YouTube: A web series dares to talk about the sexuality of young people with cancer

Health

Kidney cancer: In Nice, Dr Pagès and his team have created a drug to make "the disease curable"

• Health

• Cancer

• UNITED STATES

• Research

• Medication